A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation

Table 1 Patient demographic and baseline characteristics (ITT population)

Demographic variable	Tegaserod 6 mg b.i.d.	Placebo
	(n = 304)	(n = 303)
Age (yr)
Median	34.5	35
Range	18-80	18-78
Age group, years (n, %)
< 35	152 (50.0)	151 (49.8)
35-64	132 (43.4)	135 (44.6)
≥ 65	20 (6.6)	17 (5.6)
Sex (n, %)
Male	70 (23.0)	61 (20.1)
Female	234 (77.0)	242 (79.9)
Race (n, %)
Oriental	303 (99.7)	303 (100.0)
Other	1 (0.3)	0
Mean duration of constipation symptoms, months (SD)	100.3 (90.7)	94.9 (93.1)